Document Type : original article


1 Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;

4 Professor, Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran


Background: Since the COVID-19 pandemic began around the world, many studies have been conducted on various aspects of the disease in adults and children, but limited research has been done on blood glucose changes caused by COVID-19. So, this study was conducted to investigate blood glucose changes in children with COVID-19 hospitalized in the pediatric intensive care unit (PICU), comparing it with children hospitalized for other reasons.
Methods: This case-control study was performed on 30 COVID-19 children (group 1) during the pandemic and 29 children (group 2) who were admitted to PICU, before the prevalence of COVID-19. The control group was the same as the case group regarding age, sex, length of hospitalization, and treatment measures. Children with metabolic diseases and malignancy were excluded from the study. The data were analyzed by SPSS version 26 using chi-square and independent t-tests.
Results: Out of 59 participants, two patients had low blood sugar (BS), and one had high BS; notably, all three were in group 1. This difference was not statistically significant. Furthermore, 76.7% of children with COVID-19 and 86.2% of the other group had normal BS. The frequency distribution of BS levels in the two groups was not related to the age, gender, and hospitalization period of children.
Conclusion: This study revealed that children with COVID-19 hospitalized in PICU did not have significant BS changes compared to those hospitalized before the pandemic. In addition, gender, duration of hospitalization, and COVID-19 medication did not significantly affect blood sugar changes.


  1. Liu X, Na R, Bi Z. Challenges to prevent and control the outbreak of Novel Coronavirus Pneumonia (COVID-19). Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi. 2020; 41:E029-E.
  2. Team E. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC weekly. 2020; 2(8):113.
  3. Zheng F, Liao C, Fan Q-h, Chen H-b, Zhao X-g, Xie Z-g, Li XL, Chen CX, Lu XX, Liu ZS, Lu W, Chen CB, Jiao R, Zhang AM, Wang JT, DingXW, Zeng YG, Cheng LP, Huang QF, Wu J, Luo XC, Wang ZJ, Zhong YY, Bai Y, Wu XY, Jin RM. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Current medical science. 2020; 40(2):275-80.
  4. Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Arch Med Res. 2022; 53(1):1-8. doi: 10.1016/j.arcmed.2021.07.002.
  5. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet infectious diseases. 2020; 20(6):689-96.
  6. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T, Gao W, Cheng C, Tang X, Wu X, Wu Y, Sun B, Huang S, Sun Y, Zhang J, Ma T, Lessler J, Feng T. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet infectious diseases. 2020; 20(8):911-9.

7.Chekhlabi N, Haoudar A, Echcharii N, Ettair S, Dini N , New-Onset Diabetes with Ketoacidosis Precipitated by COVID-19 in Children: A Report of Two Cases , Case Rep Pediatr. 2021 Jul 16; 2021:5545258. doi: 10.1155/2021/5545258. E Collection 2021.

  1. Shi Y, Wu LQ, Wei P, Liao ZH. Children with type 1 diabetes in COVID-19 pandemic: Difficulties and solutions. World Journal of Clinical Pediatrics, 2022, 11.5: 408.‏
  2. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020; 14(4):303-10.
  3. Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. The lancet Diabetes & endocrinology. 2018; 6(6):476-86.
  4. Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020; 11:574541.
  5. Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, Gao Y, Ma J, Zhang H, Zhang J, Guo X, Liu X. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-center, retrospective, observational study in Wuhan. Diabetes Obes Metab. 2020; 22(8):1443-54.
  6. He B, Wang J, Wang Y, Zhao J, Huang J, Tian Y, Yang C, Zhang H, Zhang M, Gu L, Zhou X, Zhou J. The Metabolic Changes and Immune Profiles in Patients with COVID-19. Front Immunol. 2020; 11:2075.
  7. Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020; 167:108382.
  8. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020; 94(7).
  9. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019; 11(1).
  10. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47(3):193-9.
  11. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, Yu X, Dong K. Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes. BMJ Open Diabetes Res Care. 2020; 8(1).